FCR achieves long-term durable remissions in patients with IGHV-mutated CLL

Blood. 2017 Nov 23;130(21):2278-2282. doi: 10.1182/blood-2017-07-731588. Epub 2017 Oct 12.

Abstract

In chronic lymphocytic leukemia (CLL) patients with mutated IGHV, 3 recent studies have demonstrated prolonged progression-free survival (PFS) after treatment with fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy. We performed a systematic review to assess the benefit of FCR for patients with CLL and identified 5 randomized trials that met our inclusion criteria. FCR improved complete remission, PFS and overall survival vs the comparator; median PFS was not reached in the subgroup of CLL patients with mutated IGHV.

Publication types

  • Case Reports
  • Review
  • Systematic Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / therapeutic use
  • Disease-Free Survival
  • Female
  • Humans
  • Immunoglobulin Heavy Chains / genetics*
  • Immunoglobulin Variable Region / genetics*
  • Immunotherapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Middle Aged
  • Mutation / genetics*
  • Remission Induction*
  • Rituximab / therapeutic use
  • Time Factors
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use

Substances

  • Immunoglobulin Heavy Chains
  • Immunoglobulin Variable Region
  • Rituximab
  • Cyclophosphamide
  • Vidarabine
  • fludarabine